Phase 1 study evaluating safety and pharmacokinetics of tusamitamab ravtansine monotherapy in Japanese patients with advanced malignant solid tumors
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-025-02784-4 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Kei Muro und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. Hauptthemen laut MEDLINE: Neoplasms, Maytansine, Immunoconjugates. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sanofi.
Abstract (Originalsprache)
Background
Tusamitamab ravtansine (SAR408701) is an immunoconjugate that binds carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and delivers its cytotoxic payload to target cells. Here, we report findings from three dosing regimens of tusamitamab ravtansine administration in Japanese adults with advanced malignant solid tumors.
Methods
Japanese adults (aged ≥ 20 years) with CEACAM5-expressing malignant solid tumors were enrolled in this Phase 1, open-label, non-randomized, dose-escalation evaluation of tusamitamab ravtansine in three parts: (i) main dose-escalation part with every two weeks (Q2W) administration, (ii) loading dose (LD) part with Q2W administration with a LD at Cycle 1 (C1) only, and (iii) dose-escalation every three weeks (Q3W) part. Primary objectives were to evaluate the tolerability and safety of tusamitamab ravtansine.
Results
Nine patients were enrolled in the main dose-escalation part, 16 patients in the dose-escalation bis part with LD, and nine patients in the dose-escalation Q3W part. Administration of tusamitamab ravtansine resulted in a manageable safety profile with no dose-limiting toxicities reported during the observation period except for two events during dose-escalation bis Q2W part. Most common adverse events (AEs) were corneal events, gastrointestinal disorders, and metabolic events. After first administration, tusamitamab ravtansine exposure was dose proportional over the dose range 80–170 mg/m 2 . Best overall response (BOR) was stable disease, observed in all three parts; confirmed response was not observed at any dose level.
Conclusion
Tusamitamab ravtansine demonstrated a tolerable safety profile at a dose of 80–170 mg/m 2 in three different administration schedules in Japanese adults with metastatic solid tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
- Sanofi K.K., Tokyo, Japan.
- Sanofi Pharmacokinetics, Dynamics and Metabolism, Vitry-sur-Seine, France.
- Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan. tyoshino@east.ncc.go.jp.
Förderung
- Sanofi
Zitieren
APA
Muro, K., Yamazaki, K., Kadowaki, S., Mishima, S., Kawakami, T., Tanaka, T., Tada, K., Fagniez, N., Ohshima, S., & Yoshino, T. (2025). Phase 1 study evaluating safety and pharmacokinetics of tusamitamab ravtansine monotherapy in Japanese patients with advanced malignant solid tumors. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02784-4
Vancouver
Muro K, Yamazaki K, Kadowaki S, Mishima S, Kawakami T, Tanaka T, et al. Phase 1 study evaluating safety and pharmacokinetics of tusamitamab ravtansine monotherapy in Japanese patients with advanced malignant solid tumors. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02784-4
BibTeX
@article{Muro2025,
author = {Muro, Kei and Yamazaki, Kentaro and Kadowaki, Shigenori and Mishima, Saori and Kawakami, Takeshi and Tanaka, Tomoyuki and Tada, Keisuke and Fagniez, Nathalie and Ohshima, Shinobu and Yoshino, Takayuki},
title = {Phase 1 study evaluating safety and pharmacokinetics of tusamitamab ravtansine monotherapy in Japanese patients with advanced malignant solid tumors},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-025-02784-4}
}
EUVIMED